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Background: Historically, the median overall survival for follicular lymphoma (FL) has been considered to be
9-10 years, and no treatment had ever prolonged this time period. Studies conducted more than 20 years ago
demonstrated that treating patients with asymptomatic FL at the onset of the disease did not increase their
survival, and that almost 20% of these patients did not need any treatment in the first 10 years of follow-up.
Based on these facts, most clinical practice guidelines recommend active surveillance policies for patients with
asymptomatic FL.
Discussion: The introduction of antiCD-20 monoclonal antibodies, over the last 15 years, has significantly increased
the median survival rate to above 14 years. This improvement was achieved before the combination of rituximab
and chemotherapy regimens became extensively used in patients with symptomatic disease. Therefore, this
increase in survival may currently be more significant. At present, several clinical trials have evaluated low-toxicity
therapies that prolong progression-free periods, among which rituximab monotherapy, radioimmunotherapy or the
combination of rituximab with bendamustine are the most relevant. Unfortunately, these clinical trials have
included only patients with symptomatic FL. The results of a recently reported clinical trial show that treatment
with single-agent rituximab prolongs progression-free survival rates, time to new treatment and the quality of life of
asymptomatic patients, as compared with the active surveillance strategy. Longer follow-up of these results and
data regarding overall survival are awaited before this treatment can be recommended as the standard initial
therapy.
Summary: There are different therapeutic possibilities for asymptomatic FL patients, but no data are currently
available to indicate which option is the best. Patients need to understand the risks and benefits of observation
versus treatment before a final decision can be made. For patients who want active treatment the administration of
four weekly rituximab doses should be considered.Background
Follicular lymphoma (FL) is the second most common
subtype of lymphoma in Western Europe, as it repre-
sents 22-25% of non-Hodgkin´s lymphomas (NHL),
according to the WHO histological classification [1,2].
The annual incidence of FL increased from two to three
per 100,000 persons/year during the 1950s to five to
seven per 100,000 persons/year in 2009, with a preva-
lence of 40 cases per 100,000 people [3].* Correspondence: arueda@hcs.es
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reproduction in any medium, provided the orFL originates in follicular-centre B cells, usually in the
lymph nodes, and maintains the phenotypic characteristics
and gene expression of these cells. Approximately 85% of FL
patients present with chromosomal translocation t(14;18),
which leads to overexpression of the BCL-2 oncogene and
results in resistance to apoptosis. t(14,18) is not specific for
FL, as it is present in 30% of diffuse large B-cell lymphomas
(DLBCL) and even in some healthy individuals [4].
Morphologically, FL is composed of small B-cells (centro-
cytes) and large B-cells (centroblasts) that are clonally
related. The morphological distribution follows a nodal
growth pattern similar to that of the germinal centres
observed in secondary lymphoid follicles. NeoplasticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Follicular Lymphoma International Prognostic
Index (FLIPI) and Follicular Lymphoma International
Prognostic Index 2 (FLIPI 2)
FLIPI
Risk factors
• Age <60 years vs. ≥60 years
• Hemoglobin ≥12 g/dL vs. <12 g/dL
• Serum LDH≤ULN vs. >ULN*
• Ann Arbor stage I-II vs. III-IV
• No. of nodal sites ≤4 vs. >4
Risk group No. of 5–year 10–year Relative
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tumour exhibits a diffuse growth pattern [1]. FL is classified
into three grades according to the number of centroblasts
present in the tumour tissue (Table 1). In grades 1 and 2,
centrocytes prevail; in grade 3 large cells are more numer-
ous. Grade 3 is divided into 3A (when centrocytes are still
present) and 3B (characterised by the presence of solid
sheets of centroblasts). Although grade 3B FL has a worse
prognosis and its natural history and treatment are similar
to those of DLBCL, the genetic characteristics and clinical
behaviour suggest that grade 3A FL exhibits indolent be-
haviour very similar to that of grade 1-2 FL [5].
FL is the most common indolent lymphoma account-
ing for 70% of all indolent lymphomas. The treatment
used for FL has been generally accepted for other less
frequent indolent lymphomas. Usually the first symptom
is the asymptomatic presence of enlarged peripheral
nodes in the neck, and in the axillary or inguinal areas.
Occasionally, adenopathies increase and decrease in size
for prolonged intervals before diagnosis. Some patients
present a bulky abdominal mass not associated with uri-
nary/intestinal obstruction. Although patients only present
with one or two node areas that are clinically affected, the
staging study showed dissemination affecting the spleen,
liver or bone marrow in 40%, 50% and over 60% of patients,
respectively. Extranodal involvement is infrequent [6].
Once a diagnosis of FL is confirmed, the pretreatment
evaluation determines the extent of the disease and pro-
vides information about the individual's comorbidities that
are likely to have an impact on treatment options. Of par-
ticular importance is the information gathered from this
evaluation, as it is used to determine the patient's Follicular
Lymphoma International Prognostic Index (FLIPI) [7] andTable 1 Follicular lymphoma grading according to the
WHO classification1
Grading Definition
Grade 1–2 (low grade) 0–15 centroblasts per hpf*
• 1 0–5 centroblasts per hpf
• 2 6–15 centroblasts per hpf
Grade 3 >15 centroblasts per hpf
• 3A: centrocytes present
• 3B: solid sheets of centroblasts
Follicular Pattern
• Follicular >75%
• Follicular and diffuse 25–75%
• Focally follicular <25%
• Diffuse 0%**
* hpf = high-power field of 0.159 mm2.
** Diffuse areas containing >15 centroblasts per hpf are reported as DLBCL
with FL (grades 1 to 2, 3A or 3B). Note that in small biopsies the absence of
follicles may reflect a sampling error.FLIPI 2 [8] scores, which determines whether the patient is
at risk for progression (Table 2) [7,8].
Most patients are diagnosed with FL when they have
an advanced stage of the disease (less than 20% present
with stages I or II), although a significant percentage of
patients just present with an enlarged node noted by
palpation (asymptomatic FL).
FL is characterised by a chronic remission/relapse pat-
tern. FL natural history is characterised by alternating peri-
ods of treatment, achievement of a partial/total remission,
and periods free of disease and relapse or progression of
the lymphoma, which requires additional treatment. With
each new treatment remissions are less frequent and
progression-free periods are shorter. Occasionally, partial
and short spontaneous remissions can occur. Finally,
patients die after developing refractory FL, FL transfor-
mation to a more aggressive lymphoma (10-70% of cases),
acute toxicity, or of causes unrelated to the disease. How-
ever, FL is not necessarily an incurable disease. A rando-
mized study with a long follow-up period, conducted in thefactors OS** OS** risk
Good 0–1 91% 71% 1
Intermediate 2 78% 51% 2.3




• Longest diameter of the largest involved node> 6 cm
• Bone marrow involvement
• Hemoglobin level< 12 gr/L
• Age older than 60 years








Low 0 90.9% 79.5% 1
Intermediate 1-2 69.3% 51.2% 3.19
High 3-5 51.3% 18.8% 5.76
* ULN: under limits normal.
** OS: overall survival.
*** PFS: progression free survival.
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never relapse or die without known disease at nearly
20 years after treatment [9].
With the treatments that were applied 10-15 years ago in
the so-called pre-rituximab era, the median survival ranged
from 9 to 10 years and no treatment was shown to increase
overall survival [10]. The aim of the treatment was to im-
prove patients’ quality of life. Therefore, asymptomatic
patients were not treated until the disease was progressive
(watch-and-wait strategy). Thus, patients were spared the
acute and late toxic effects of the treatment.
In the past 15 years, the introduction of rituximab into
the treatment of patients with FL has resulted in a signifi-
cant change in the diseases’ prognosis and natural history.
The median survival has increased to approximately
14 years [11], and progression-free survival periods without
treatment have been extended to nearly 5 years [12]. All
this has been achieved with just a slight increase in toxicity.
Unfortunately, advanced-stage FL is still incurable for
the majority of patients. Thus, current therapies are
aimed at achieving optimal palliation by inducing long
periods of durable remissions with assumable acute and late
toxicity, which limit the potential development of shared
"cross-resistance" to other therapies in the future [13].
In this new setting and in the light of recent evidence,
application of the “watch and wait” policy to asympto-
matic patients should be reviewed.
Discussion
Definition of asymptomatic follicular lymphoma
There is not a universally accepted definition with which to
identify a LF patient as being asymptomatic. The definitions
available were provided in retrospective studies by coopera-
tive groups that sought to describe clinical risk factors for
disease progression. At present, the most common criteria
for identifying low-risk/low-tumour burden asymptomatic
patients are those established by the Groupe d´Etude des
Lymphomes Folliculares (GELF) [14,15]. According to this
group, low-risk/low-tumour burden asymptomatic patients
who are likely to remain untreated were those who did not
meeting any of the following criteria:
 Lymph node or extranodal mass with a
diameter> 7 cm
 Involvement of at least three nodal regions, each
with a diameter> 3 cm
 Systemic symptoms/B-symptoms
 Splenomegaly below the umbilicus
 Compression syndrome (ureter, intestinal, orbital,
and others)
 Serous pleural/peritoneal effusion (regardless of cell
count)
 Leukemic expression with circulating tumour cell
count> 5.0 x 109 x L Cytopenias (concentration of granulocytes< 1.0 x
109 x L and platelet count< 100 x 109 x L)
These are the criteria employed in most clinical trials
and recommended by the Clinical Guidelines for the
Treatment of Follicular Lymphoma of the American Na-
tional Comprehensive Cancer Network (NCCN) [16].
Clinical trials supporting the “watch-and-wait” strategy
Three randomized trials assessed the effectiveness of active
surveillance without first-line treatment of advanced FL.
The American National Cancer Institute (NCI) randomized
89 patients with advanced indolent lymphoma to “watch
and wait” or to undergo aggressive combined modality
treatment with prednisone, methotrexate, adriamycin,
cyclophosphamide, etoposide, mechlorethamine, vincristine
and procarbazine (ProMACE-MOPP), followed by total
nodal irradiation (TNI) [17]. Survival in both groups at
5 years was over 75%, but progression-free survival was
51% in the chemotherapy group and 12% in the watchful
waiting group.
In France, the GELF group randomized patients with
advanced FL and low-tumour-burden to the watch-and-
wait strategy, or to treatment with prednimustine or
interferon alfa [14]. Overall survival at 5 years was simi-
lar for the three arms of the study.
The most significant study was that conducted by the
British National Lymphoma Investigation Group, which
randomized 309 patients with advanced indolent lymph-
oma (204 with FL) to immediate treatment with chlor-
ambucil or to systemic therapy deferred until disease
progression [18]. In both arms modest doses of palliative
radiotherapy for the treatment of symptomatic adenopa-
thies were permitted. With a 16-year median follow-up,
the overall survival time was similar between both
groups. Ten years following the initiation of the study, 19%
of the patients treated with the watch and wait approach
had still not required systemic therapy (40% of patients
older than 70 years). However, it should be noted that the
patients on immediate systemic treatment had higher re-
sponse rates (63% of complete remission) than the patients
who were initially untreated (27% of complete remission).
These three randomized studies revealed that 60-75%
of the patients treated with the watchful-waiting proto-
col required treatment during the first 2-3 years of
follow-up.
The situation in stage I-II follicular lymphoma, accord-
ing to the Ann Arbor staging index, differs. The admin-
istration of radiotherapy (24-36 Gy) to involved nodal
areas resulted in progression in 50% of the patients at
10 years [19,20]. However, when high morbidity is
expected due to radiotherapy, or when the patient
refuses to receive radiotherapy, watchful waiting can be
a reasonable strategy. Two retrospective studies have
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(85% at 10 years) and, with a median follow-up period of
7.2 and 6.3 years, progression was not observed in 63%
and 50% of the patients, respectively, so therapy was not
required [21,22].
Active surveillance or watch and wait: Advantages and
disadvantages
The watch-and-wait policy applied to asymptomatic FL
patients involves more intensive surveillance than in
patients in remission after first-line treatment. This is
the reason why it is named “active surveillance” (or
“watchful waiting”). Anticancer treatment is not admi-
nistered, but surveillance visits are more frequent (every
3 months) in order to detect symptomatic progression
of the disease and initiate treatment before the onset of
further complications.
The advantages and disadvantages of deferring antic-
ancer treatment in asymptomatic FL patients in the pre-
rituximab era are shown in Table 3. The effectiveness of
FL therapies has improved in recent years. Long remis-
sion periods are now achieved and, in certain cases, by
treatments involving low acute toxicity risk. Therefore,
nowadays the main disadvantage of undertaking active
surveillance for indolent FL is that a treatment with a
very favourable therapeutic index (efficacy/toxicity) is
delayed.
What has changed in the rituximab era?
In 1997, rituximab was approved for the treatment of re-
fractory/relapsed FL. Since then, this anti-CD-20 mono-
clonal antibody has proven to be effective when used as
a monotherapy or in combination with chemotherapy at
different stages in the FL natural history. Radioimmu-
notherapy and other antineoplastic agents have also
demonstrated significant antitumor activity. TheTable 3 Advantages and disadvantages of deferring
treatment in asymptomatic FL patients (watchful waiting)
Advantages
• Patients are spared the effects of acute toxicity
• Patients are spared the effects of serious late toxicity (i.e.,
myelodysplasia)
• The development of shared "cross-resistance" to other therapies is
avoided
Disadvantages
• Risk of severe complications associated with the disease during the
interval between visits
• The chances of obtaining a good antitumor response with the first
course of treatment can decrease [16]
• The risk of FL transformation into aggressive lymphoma can increase
[23]
• Anxiety caused by the fact of suffering an oncologic disease that is not
being treatedintroduction of these drugs has modified some of the
arguments on which active surveillance – as a treatment
strategy in asymptomatic patients – is based.
Overall survival has increased
Historically, the median overall survival for FL was con-
sidered to be 9-10 years, and no treatment had ever pro-
longed this time period [10]. However, the introduction
of anti CD-20 monoclonal antibodies has significantly
increased the median survival rate to above 14 years
[11]. This improvement was detected before the combin-
ation of rituximab and chemotherapy regimens was ex-
tensively employed as an early treatment, and before the
use of monotherapy with rituximab as a maintenance
therapy after induction treatment. Both strategies have
been shown to increase survival rates since 2003 [24,25].
Therefore, this increase in survival may currently be
more significant.
First-line treatment with immunochemotherapy may
prolong progression-free periods and the time to the
next treatment
The benefit of adding rituximab to combination chemo-
therapy (immunochemotherapy) has been demonstrated
in several randomized trials of chemotherapy with or
without rituximab [26-30]. All of these trials have
demonstrated improved response rates and time to pro-
gression when rituximab was added; many also showed
an improvement in overall survival with rituximab.
Progression-free survival rates at 3 years were increased
by approximately 15 to 30%.
An international multicenter trial randomly assigned
321 patients with previously untreated stage III/IV FL to
receive eight cycles of CVP (cyclophosphamide, vincris-
tine and prednisone) or CVP plus rituximab (R-CVP)
[26]. The patients assigned to R-CVP demonstrated sig-
nificantly higher rates of overall (81% versus 57%) and
complete (41% versus 10%) responses. At a median
follow-up period of 30 months, R-CVP improved me-
dian time to progression (32 months versus 15 months).
At a median follow-up period of 53 months, the patients
who received R-CVP had significantly higher rates of 4-
year overall survival (83% versus 77%) [27].
In a second randomized trial, 428 patients with un-
treated advanced-stage FL were randomly assigned to
treatment with CHOP (cyclophosphamide, doxorubicin,
vincristine and prednisone) with or without rituximab
[28]. The patients assigned to R-CHOP had significantly
superior 2-year progression-free survival rates (approxi-
mately 85% versus 65%) and overall survival rates (95%
versus 90%). Another trial randomly assigned 201
patients with previously untreated stage III/IV FL to re-
ceive eight cycles of MCP (mitoxantrone, chlorambucil
and prednisone) or MCP with rituximab (R-MCP) [29].
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were treated with interferon maintenance until relapse.
Overall (92% versus 75%) and complete (50% versus
25%) response rates were higher in the R-MCP treat-
ment arm. At a median follow-up of 47 months, the
patients assigned to R-MCP demonstrated superior me-
dian progression-free (not reached versus 29 months)
and 4-year overall survival rates (87% versus 74%).
In a French prospective trial, 185 patients with previ-
ously untreated advanced-stage FL were randomly
assigned to treatment with chemotherapy (cyclophos-
phamide, doxorubicin, etoposide, prednisone, plus inter-
feron) with or without rituximab [30]. After a median
follow-up of 5 years, the patients assigned to chemother-
apy plus rituximab group had significantly higher rates
of complete response (67% versus 50%) and longer
event-free survival (53% versus 37%) than those who
were assigned to the chemotherapy without rituximab
group.
Low-toxicity treatments can prolong progression-free
survival
Initial treatment with single-agent rituximab appears
promising given its low toxicity profile and good re-
sponse rates. However, long-term follow-up of such an
approach is limited. The following phase-II trials evaluated
rituximab (375 mg/m2 IV per week for a minimum of 4
consecutive weeks) as initial therapy in patients with FL.
In a prospective trial of single-agent rituximab in 62
chemotherapy-naive patients, most of whom had stage
III or IV disease, overall response rates at 6 weeks and at
maximum response were 47% and 73%, respectively,
with 7% and 37% complete remissions, respectively [31].
At a median follow-up period of 30 months, median
progression-free survival was 34 months. Toxicity was
mostly infusion related and of brief duration.
A second trial evaluated 50 patients with stage II to IV
FL and low tumour burden (no nodal or extranodal
mass> 7 cm, B symptoms, splenomegaly, pleural effu-
sion, ascites, organ compression, and elevated serum lac-
tate dehydrogenase or beta-2-microglobulin) [32]. The
overall response rate at 50 days was 73%. The median
time to progression was approximately 13 months. Tox-
icity was minimal; the number and severity of adverse
events decreased with subsequent infusions.
The North Central Cancer Treatment Group enrolled
37 patients with untreated follicular grade 1 NHL and
measurable stage III/IV disease [33]. Patients received
intravenous rituximab at a dose of 375 mg/m2 four times
weekly and no maintenance therapy was provided. The
overall response rate was 72%, with 36% complete remis-
sion. The median time to progression was 2.2 years and
fourteen (39%) patients remained in unmaintained re-
mission with a median follow-up of 2.6 years.An international trial of 202 patients with previously
untreated or relapsed/refractory FL involved the admin-
istration of rituximab four times weekly [34]. The 151
patients with responding or stable disease at week 12
were randomised to no further treatment or prolonged
rituximab maintenance every 2 months for four doses.
At a median follow-up of 35 months, patients who
received the prolonged rituximab maintenance treat-
ment had a significantly longer median event-free-
survival (23 months versus 12 months) when compared
with those randomised to observation with no apparent
increase in toxicity. This benefit appears to be main-
tained during long-term follow-up with 35% of the
responders still in remission at 8 years after treatment
[35]. Of note, 45% of the newly diagnosed patients in
this study treated with extended-schedule rituximab
were in remission at 8 years.
Anti-CD20 radioimmunoconjugates, for example ibri-
tumomab tiuxetan and tositumomab, have demonstrated
efficacy in relapsed or refractory FL. One prospective
trial investigated the use of single-agent tositumomab in
patients with selected low tumour burden who had had
previously untreated FL. A single course of treatment
with tositumomab was given to 76 previously untreated
patients with FL, and resulted in overall and complete
response rates of 95% and 75%, respectively, and 5-year
overall survival and progression free survival rates of
89% and 59%, respectively [36].
Bendamustine plus rituximab (B-R) is a new immuno-
chemotherapeutic regimen with high activity and low
toxicity in relapsed and refractory FL [37] that is being
evaluated as a first-line therapy. In 513 patients with un-
treated advanced follicular, indolent and mantle-cell
lymphoma, bendamustine (90 mg/m2 on days 1 and 2)
plus rituximab (375 mg/m2 on day 1) given every 28 days
for six cycles was compared with standard R-CHOP for
six cycles; it also achieved statistically superior
progression-free survival (54.8 months versus
34.8 months) and event-free survival (54 months versus
31 months) with less toxicity, including lower rates of
grade-3 and -4 neutropenia (10.7% versus 46.5%) and
leukocytopaenia (12.1% versus 38.2%). Alopecia did not
occur, and neuropathy was very uncommon in the B-R
treated patients. There was no difference in overall sur-
vival at a median follow-up period of 32 months [38].
Randomized clinical trials with rituximab in asymptomatic
follicular lymphoma
The large amount of information that has been gener-
ated over the last 15 years on the treatment of LF has
not changed clinical opinion regarding the implementa-
tion of active surveillance in the treatment of asymptom-
atic LF. So far, clinical trials have only included either
patients with symptomatic FL or mixed symptomatic
Table 4 Responses in the three arms of the rituximab
versus “watch-and-wait” study
Time of response evaluation 7 months 13 months 25 months
Arm A (W&W)
+CRu 3 (2%) 6 (3%) 5 (4%)
PR 6 (3%) 7 (4%) 5 (4%)
ORR 9 (5%) 13 (7%) 10 (8%)
Arm B (Rx4)
CR+CRu 35 (43%) 36 (44%) 30 (40%)
PR 25 (30%) 22 (27%) 10 (13%)
ORR 60 (73%) 58 (71%) 40 (53%)
Arm C (Rx4RM)
CR+CRu 100 (54%) 122 (67%) 98 (70%)
PR 61 (33%) 36 (20%) 12 (9%)
ORR 161 (87%) 158 (87%) 110 (79%)
p value (Arm B vs Arm C) p= 0.0216 p= 0.0077 p< 0.0001
W&W: watch and wait; Rx4: rituximab four weekly doses; Rx4+RM: rituximab
four weekly doses plus rituximab maintenance; CR: complete response; CRu:
undetermined complete response; PR: partial response; ORR: overall response
rate.
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tion that would allow for separate analysis of the data
obtained. In some phase II trials – such as those con-
ducted with single-agent rituximab alone [32] or with
tositumomab [36] – patients were selected with low-
tumour burden using different criteria from those used
in the GELF group.
The results of two randomized clinical trials including
only asymptomatic LF patients conducted in the rituxi-
mab era have recently been reported. The British Na-
tional Cancer Research Institute Lymphoma Group
studied the effect of a low-toxicity therapy proven to be
effective on asymptomatic FL patients. Their goal was to
assess whether single-agent rituximab therapy signifi-
cantly delayed the initiation of chemotherapy or radio-
therapy, as compared with active surveillance in
advanced asymptomatic FL patients according to the
GELF groups’ criteria [39]. A total of 463 patients were
randomised to three treatment arms:
 Active surveillance with regular visits every
2 months
 Rituximab at 375 mg/m2/week for 4 weeks
 Rituximab at 375 mg/m2/week for 4 weeks followed
by rituximab maintenance at 375 mg/m2 every
2 months for two years
During the follow-up period, painful peripheral adeno-
pathies were not treated with radiotherapy, and the cri-
teria for initiating a new anti-lymphoma therapy were
established in the protocol. Three quarters of the
patients recruited had low/intermediate risk (according
to the FLIPI index). Regarding toxicity, only 10 grade 3-
4 toxicity events were reported (half were infections)
among the 276 patients treated with rituximab (3.5%).
Table 4 shows the response rate for each group. With
a median follow-up of 32 months, 44% of the patients in
the active surveillance group had initiated anti-
lymphoma treatment, while the rate for the patients re-
ceiving rituximab alone was 23%; this rate was 10% for
the patients treated with rituximab plus maintenance
therapy. Table 5 shows disease-free survival rates and
the time to next antilymphoma treatment for the three
trial arms. So far, no difference has been detected in the
overall survival rate (95% at 3 years). However, the
follow-up period was too short to assess this parameter.
Preliminary results from a quality of life (QOL) ana-
lysis of this trial showed that the patients who received
treatment with rituximab had reduced anxiety and
improved functional well-being [40]. At baseline, patient
QOL scores were similar or superior to those of the gen-
eral population (as assessed by the FACT-G question-
naire), with the exception of inferior emotional well-
being. Although the patients treated with the “watch andwait” protocol also reported improvements in some
QOL parameters, the greatest improvements in emo-
tional and functional well-being were observed in the
patients who received either rituximab maintenance
therapy or monotherapy [40].
The Eastern Cooperative Oncology Group have reported
the E4402 randomized phase III study (RESORT) compa-
ring two different rituximab dosing strategies for low
tumour burden FL (according to the GELF criteria) [41].
Patients received rituximab at 375 mg/m2 weekly for four
doses and responders were randomized to rituximab main-
tenance (MR) (single dose rituximab every 3 months) or
rituximab retreatment (RR) (rituximab four times weekly at
disease progression). Each strategy was continued until
treatment failure. The primary endpoint, time to treatment
failure (TTTF), was defined as progression within 6 months
of last rituximab dose, no response to rituximab retreat-
ment, initiation of alternative therapy or inability to
complete protocol therapy. Secondary endpoints included
time to first cytotoxic therapy, quality of life and safety.
Of 384 patients enrolled, complete or partial response
was achieved in 274 (71%), who were then randomized
to MR (n = 140) or RR (n = 134). With a median follow-
up of 3.8 years, TTTF was 3.9 years for MR versus
3.6 years for RR (p = not significant). At 3 years, 95% of
MR versus 86% of RR patients (p = 0.027) remained free
of first cytotoxic therapy, but the mean number of ritux-
imab doses per patient (including the four induction
doses) was 15.8 (range 5-31) for MR and 4.5 (range 4-16)
for RR. At 12 months post randomization, there was no
discernible difference in health related QOL and anxiety
between the two arms.
Table 5 Progression-free survival and time to next antilymphoma treatment in the rituximab versus “watch-and-wait”
study
PNRNT 3 years Differences between arms HR p value PFS 3 years Differences between arms HR p value
W&W 48% Rx4 vs W&W 0.37 p< 0.001 33% Rx4 vs W&W 0.46 p< 0.001
Rx4 80% Rx4+ RM vs W&W 0.20 p< 0.001 60% Rx4+ RM vs W&W 0.21 p< 0.001
Rx4 + RM 91% Rx4 + RM vs Rx4 0.57 p = 0.10 81% Rx4+ RM vs Rx4 0.43 p< 0.001
PNRNT: patients not receiving next therapy; PFS: progression free survival; HR: hazard ratio; W&W: watch and wait; Rx4: four weekly doses of rituximab;
Rx4+RM: four weekly doses of rituximab plus rituximab maintenance.
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The active surveillance therapy strategy in asymptomatic
FL patients is based on the disease’s natural history and
on the results of trials conducted many years ago. Such
trials included patients with different histologic types of
asymptomatic lymphoma (based on classifications that
are no longer used). Similarly, the treatments used in the
past were less effective and more toxic than those used
today.
At present, new low-toxicity therapies that prolong
progression-free periods and time to new anti-
lymphoma therapy are available, among which rituximab
monotherapy (with or without maintenance), radioim-
munotherapy or the combination of rituximab with
bendamustine are the most relevant. Unfortunately, the
impact of current therapies on asymptomatic FL patients
is still unclear, as only one specific clinical trial has been
conducted in this population.
The results of a recently reported clinical trial [39]
show that treatment with single-agent rituximab pro-
longs progression-free survival rates, time to new treat-
ment and the quality of life, as compared with the active
surveillance strategy applied to asymptomatic FL
patients. However, we do not know if “progression-free
survival” or the “time to next treatment” (the main end-
point of the study) are the best end points to decide
which option is better in this patient population. It is ob-
vious that patients treated with rituximab will have a su-
perior response rate and longer time to the next
treatment than those who were just observed. The crit-
ical point is what is going to happen after the next treat-
ment (first-line treatment for observed patients; second-
line for the other patients) and, ultimately, with the
overall survival of the patients. Furthermore, there is
some concern regarding the fact that patients relapsing
after rituximab induction plus 2-year maintenance treat-
ment could be particularly resistant to standard immu-
nochemotherapy. Longer-term follow-up of these results
is awaited before this treatment can be recommended as
the standard initial therapy.
So, it is time to leave the “watch-and-wait” strategy in
newly diagnosed asymptomatic follicular lymphoma
patients?. Not yet but we are getting closer through ef-
fective and less toxic treatments. In this clinical scenario
the initial discussion with the patient is typically a longone. Patients need to understand the entire situation of
the disease and the risks and benefits of observation ver-
sus treatment. The physician must also look at the entire
patient, other comorbidities, the patient's mindset and
other factors before a final decision can be made. For
patients who want active treatment the administration of
four weekly rituximab doses should be considered. How-
ever, the administration of rituximab maintenance
should be avoided until further data based on longer
follow-up periods are available.
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